| First Author | van de Ven M | Year | 2018 |
| Journal | J Pathol | Volume | 246 |
| Issue | 1 | Pages | 41-53 |
| PubMed ID | 29877575 | Mgi Jnum | J:268685 |
| Mgi Id | MGI:6268015 | Doi | 10.1002/path.5105 |
| Citation | van de Ven M, et al. (2018) BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. J Pathol 246(1):41-53 |
| abstractText | Hereditary breast cancers in BRCA1 mutation carriers are mostly estrogen receptor alpha (ERalpha)-negative and progesterone receptor (PR)-negative; however, hormone depletion via bilateral oophorectomy does result in a marked reduction in breast cancer risk, suggesting that BRCA1-associated breast tumorigenesis is dependent on hormone signaling. We used geneticaly engineered mouse models to determine the individual influences of ERalpha and PR signaling on the development of BRCA1-deficient breast cancer. In line with the human data, BRCA1-deficient mouse mammary tumors are ERalpha-negative, and bilateral ovariectomy leads to abrogation of mammary tumor development. Hormonal replacement experiments in ovariectomized mice showed that BRCA1-deficient mammary tumor formation is promoted by estrogen but not by progesterone. In line with these data, mammary tumorigenesis was significantly delayed by the selective ERalpha downregulator fulvestrant, but not by the selective PR antagonist Org33628. Together, our results illustrate that BRCA1-associated tumorigenesis is dependent on estrogen signaling rather than on progesterone signaling, and call into question the utility of PR antagonists as a tumor prevention strategy for BRCA1 mutation carriers. Copyright (c) 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
